Connect with us

News

ADOCIA Reports First Quarter 2024 Financial Results and Provides Business Update

FinCrypto Staff

Published

on

ADOCIA Reports First Quarter 2024 Financial Results and Provides Business Update

  • The cash position of 10.2 million euros as of March 31, 2024 includes proceeds from financing from March 20241, presenting:

    • 2 million euros invested by three members of management and Vester Finance, the Company’s second largest shareholder after the Soula family

    • An equity financing facility (“PACEO2”) with Vester Finance for a maximum of 1.7 million shares, the full utilization of which would extend the Company’s cash flow until the third quarter of 2025

  • Continued partnership discussions with Sanofi on M1Pram and preparations for phase 2b trial in the United States

LYON, France, May 14, 2024–(BUSINESS WIRE)–Regulatory news:

Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the first quarter of 2024 and provides a business update.

We continue to pursue our priority of concluding a partnership with Sanofi on M1Pram as quickly as possible“, declared Olivier Soula, CEO of Adocia. “At the same time, we are pleased to have expanded our cash flow, allowing us to execute our plans for our other programs in cell therapy and obesity.“.

First Quarter 2024 Financial Results
Financial highlights for the quarter include the following:

Recipe detail

In thousands of euros, IFRS standards (unaudited)

03/31/2024
(3 months)

03/31/2023
(3 months)

Licensing revenue

109

Research and collaboration agreements

703

Revenue

812

Q1 2023 revenues were primarily due to Adocia’s work under its collaboration with Tonghua Dongbao on the BioChaperone® Combo (BC Combo) project to conduct three clinical studies in Europe. These studies, whose results were positive, were completed in 2023 and therefore did not generate any revenue in the first quarter of 2024.

Net cash position

The Company’s cash position was €10.2 million as of March 31, 2024, compared to €13.0 million as of December 31, 2023. This includes €3 million received in March 2024 as part from raising private placement funds of 2 million euros and 1 million euros advance on the equity financing line with Vester Finance. Cash used to finance operations during the first quarter of 2024 was €5.8 million, compared to €7.8 million in the prior-year quarter.

Net debt (excluding the impacts of IFRS 16) was 5.7 million euros on March 31, 2024, unchanged compared to December 31, 2023. The debt consists of a State Guaranteed Loan (PGE). Under the renegotiated August 2023 repayment schedule, the next payment will be in the third quarter of 2024.

The story continues

The Company’s cash position of 10.2 million euros as of March 31, 2024 is sufficient to finance currently planned operations until the third quarter of 2025, excluding any income from existing or future partnerships, but assuming full use of the line equity financing agreement (“PACEO”) signed in March 2024 with Vester Finance.

Adocia remains in exclusive negotiations with Sanofi for a global partnership on M1Pram and expects two payments of US$10 million each, tied to the progress of its BioChaperone® Lispro and BioChaperone® Combo projects with Tonghua Dongbao.

Highlights from the first quarter of 2024

M1Pram

Following the July 2023 agreement between Sanofi and Adocia, negotiations continue with the aim of structuring a global partnership.

M1Pram is a fixed-dose combination of insulin and amylin analogs designed to address the unmet medical need for obesity in people with type 1 diabetes.

Preparations for the phase 2b clinical program in the United States, which will include 140 patients with type 1 diabetes and BMI >30kg/m², continue with the completion of production of the first clinical batch. The study is expected to begin in the third quarter of 2024.

BioChaperone® in partnership with Tonghua Dongbao

BioChaperone® Lispro

The two phase 3 studies with BioChaperone® Lispro are progressing on schedule. Led by partner Tonghua Dongbao in China, the program is enrolling 1,500 people with type 1 or type 2 diabetes. The patient’s last appointment, currently scheduled for the second half of 2024, will generate a payment of US$10 million (out of a maximum of US$30 million in future payments, followed by royalties on net product sales).

BioChaperone® Combo

Tonghua Dongbao is actively preparing upcoming clinical studies of BioChaperone® Combo and expects to submit the program for approval by CDE, the Chinese regulatory authority. Treatment of the first patient in the first Phase 3 study of the BioChaperone® Combo, which is scheduled for the second half of 2024, will trigger a payment of US$10 million (out of a maximum of US$50 million in future milestone payments, followed royalties on net product sales).

AdoShell® Islets

The AdoShell platform, an immunoprotective biomaterial for cell therapy, is attracting interest from potential pharmaceutical partners.

The latest preclinical results were the subject of an oral presentation at the Société Francophone du Diabète (SFD) congress in March 2024 by Dr. Rosy Eloy, Medical Director of Adocia. Additional data will be presented at the American Diabetes Association (ADA) 84th Scientific Sessions in June 2024 in a presentation titled: “AdoShell®, a non-fibrotic encapsulation system for human islet transplantation shows promising results for clinical application as a cure for people with type 1 diabetes“.

Adocia is preparing to validate the proposed clinical development plan with regulatory authorities. AdoShell® islets could be in clinical trials as early as 2025.

AdOral®

Adocia has developed a technology for the oral administration of peptides that should allow the change from injectable to oral form. An initial application to semaglutide (GLP-1) validated this technology in preclinical trials.

The AdOral® technology is currently being tested on peptides from two pharmaceutical partners, and the encouraging results obtained to date are the basis for discussions to determine next steps in these collaborations.

AdoGel®

Designed for the delivery of long-acting peptides, AdoGel® is currently being tested in semaglutide (GLP-1). Preclinical results will be presented at the ADA (American Diabetes Association) Scientific Sessions in a presentation titled: “Development of a monthly semaglutide formulation based on an innovative injectable and biodegradable hydrogel“.

About Adócia

Adocia is a biotechnology company specialized in the discovery and development of therapeutic solutions in the area of ​​metabolic diseases, mainly diabetes and obesity.

The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) BioChaperone® technology for the development of new generation insulins and products that combine different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with initial application in pancreatic cell transplantation; and 4) AdoGel®, a long-acting drug delivery platform.

Adocia holds more than 25 patent families. Headquartered in Lyon, the company has around 80 employees. Adocia is listed on the regulated Euronext™ Paris market (Euronext: ADOC; ISIN: FR0011184241).

Disclaimer

This press release contains certain forward-looking statements regarding Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks, including those set forth in the “Risk Factors” section of the universal registration document that has been filed with the French Autorité des marchés financiers on April 29, 2024, available at www.adocia.com. These risks include uncertainties inherent in Adocia’s short- or medium-term working capital needs, research and development, future clinical data, analysis and developments in economic conditions, financial markets and the markets in which Adocia operates, which could impact the Company’s short-term financing needs and its ability to raise additional funds.

The forward-looking statements contained in this press release are also subject to risks not yet known by Adocia or not considered material by Adocia at this time. The occurrence of all or part of such risks could cause Adocia’s actual results, financial condition, performance or achievements to be materially different from those set forth in the forward-looking statements.

1 See the company’s press release dated March 21, 2024.
two PACEO: Capital Increase Program by Exercise of Options

View the original version on businesswire.com: https://www.businesswire.com/news/home/20240514137379/en/

Contacts

Adócia
Oliver Soula
CEO
contactinvestisseurs@adocia.com
+33 (0)4 72 610 610
www.adocia.com

Ulysse Communication
Adocia Press and Investor Relations
Bruno Arab
Nicolas Entz
adocia@ulysse-communication.com
+ 33 (0)6 87 88 47 26

Source

We are the editorial team of FinCrypto, where seriousness meets clarity in cryptocurrency analysis. With a robust team of finance and blockchain technology experts, we are dedicated to meticulously exploring complex crypto markets with detailed assessments and an unbiased approach. Our mission is to democratize access to knowledge of emerging financial technologies, ensuring they are understandable and accessible to all. In every article on FinCrypto, we strive to provide content that not only educates, but also empowers our readers, facilitating their integration into the financial digital age.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Información básica sobre protección de datos Ver más

  • Responsable: Miguel Mamador.
  • Finalidad:  Moderar los comentarios.
  • Legitimación:  Por consentimiento del interesado.
  • Destinatarios y encargados de tratamiento:  No se ceden o comunican datos a terceros para prestar este servicio. El Titular ha contratado los servicios de alojamiento web a Banahosting que actúa como encargado de tratamiento.
  • Derechos: Acceder, rectificar y suprimir los datos.
  • Información Adicional: Puede consultar la información detallada en la Política de Privacidad.

News

Breakfast on Wall Street: The Week Ahead

FinCrypto Staff

Published

on

Wall Street Breakfast profile picture

The spotlight next week will shift somewhat to the Federal Reserve’s second-quarter earnings season and monetary policy. Market watchers will be treated to results from several major names, including Dow 30 components Goldman Sachs (GS), UnitedHealth (UNH), Johnson & Johnson (JNJ) and American Express (AXP), along with streaming giant Netflix (NFLX).

The Fed will still attract some attention as investors will be eager to hear from a packed lineup of central bank speakers just before the policy meeting lockout period.

In terms of the economic calendar, after fifteen days of labor market and inflation indicators, activity data will gain momentum in the form of the latest retail sales and industrial production reports.

Earnings Highlight: Monday, July 15 – Goldman Sachs (GS) and BlackRock (Black). See the full earnings calendar.

Earnings Highlight: Tuesday, July 16 – UnitedHealth (UNH), Bank of America (BAC), Progressive (PGR), Morgan Stanley (IN), PNC Financial (PNC) and JB Hunt Transport (JBHT). See the full earnings calendar.

Earnings Highlight: Wednesday, July 17 – Johnson & Johnson (JNJ), US Bancorp (USB), Morgan Children (KMI), United Airlines (UAL) and Ally Financial (ALLY). See the full earnings calendar.

Earnings Highlight: Thursday, July 18 – Netflix (NFLX), Abbott Laboratories (ABT), Black stone (BX), Domino’s pizza (ZDP) and Taiwan Semiconductor Manufacturing (TSM). See the full earnings calendar.

Earnings Highlight: Friday, July 19 – American Express (AXP), Halliburton (THANKS) and Travelers (VRT (return to recoverable value)) See the full earnings calendar.

IPO Observation: Hospital and healthcare clinic operator Ardent Health Partners (TARDT), insurance service provider Twfg (TWFG) and the biotechnology company Lirum Therapeutics (LRTX) are expected to price their IPOs and begin trading next week. The analyst quiet period ends at Rectitude (RECT) to free up analysts to publish ratings.

Source

Continue Reading

News

Trump shooting: Gold could hit record high, dollar and cryptocurrencies set to jump

FinCrypto Staff

Published

on

Police cars outside the residence of Thomas Matthew Crooks, the alleged shooter at a Trump rally on Saturday, investigate the area in Pennsylvania. In the aftermath of the incident, one rally attendee was killed, two rally attendees are in critical condition and Donald Trump suffered a non-fatal gunshot wound. The shooter is dead after being killed by the United States Secret Service. (Photo by Kyle Mazza/Anadolu via Getty Images)

Police cars outside the residence of Thomas Matthew Crooks, the suspected shooter at a Trump rally on Saturday, investigate the area in Pennsylvania. Following the incident, one rally attendee was killed, two rally attendees are in critical condition and Donald Trump suffered a non-fatal gunshot wound. The shooter is dead after being shot dead by the United States Secret Service. (Photo by Kyle Mazza/Anadolu via Getty Images)

Investors will initially favor traditional safe-haven assets and may lean toward trades more closely tied to former President Donald Trump’s chances of winning the White House after he survived an assassination attempt, according to market watchers.

“There will undoubtedly be some protectionist or safe-haven flows into Asia early this morning,” said Nick Twidale, chief market analyst at ATFX Global Markets. “I suspect gold could test all-time highs, we’ll see the yen being bought and the dollar, and flows into Treasuries as well.”

Early market commentary suggested Trump’s shooting at a rally in Pennsylvania on Saturday could also prompt traders to increase his likelihood of success in the November election. His support for looser fiscal policy and higher tariffs is generally seen as likely to benefit the dollar and weaken Treasuries.

An indicator of market sentiment heading into the weekend: Bitcoin surged above $60,000, likely reflecting Trump’s pro-crypto stance.

Other assets positively linked to the so-called Trump trade include stocks of energy companies, private prisons, credit card companies and health insurers.

Traders will also be closely watching market measures of expected volatility on Monday, such as those in the tariff-sensitive Chinese yuan and Mexican peso, which have begun to price in the U.S. vote.

Trump said he was shot in the right ear after a shooting at his rally. His campaign said in a statement that he was “fine” after the incident, which prompted him to rush off the stage.

“Currencies will be the first major market on Monday in Asia to react to the weekend’s shots. There’s potential for extra volatility, and getting a clear reading could be especially difficult because liquidity will be hurt by Japan’s national holiday,” said Garfield Reynolds, Asia team leader for Bloomberg Markets Live.

Strategists had already expected a volatile run-up to the election, particularly as Democrats are still agonizing over President Joe Biden’s candidacy after his poor performance in last month’s debate raised questions about his age. Investors were also grappling with the possibility that the election could end in a drawn-out dispute or political violence.

But there is little precedent for events like those in Pennsylvania. When President Ronald Reagan was shot four decades ago, the stock market plunged before closing early. The next day, March 31, 1981, the S&P 500 rose more than 1% and benchmark 10-year Treasury yields fell 9 basis points to 13.13%, according to data compiled by Bloomberg.

Bond investors should pay particular attention as the attack is likely to boost Trump’s election chances and ultimately lead to concerns about the fiscal outlook, according to Marko Papic, chief strategist at California-based BCA Research Inc.

“The bond market must at some point become aware of President Trump’s greater chances of winning the White House than any of his rivals,” Papic wrote. “And I continue to believe that as his chances increase, so too must the likelihood of a bond market revolt.”

Kyle Rodda, senior financial markets analyst at Capital.com, said he was seeing client flows into Bitcoin and gold following the shooting.

“This news marks a turning point in American policy norms,” he said. “For markets, it means safe-haven trades, but more tilted toward non-traditional safe-havens.”

Source

Continue Reading

News

Latest Business News Live Updates Today, July 11, 2024

FinCrypto Staff

Published

on

Latest Business News Live Updates Today, July 11, 2024

Follow us for stories on Bill Gates, Elon Musk, Mukesh Ambani, Gautam Adani as we bring you everything that’s happening in the business world. Follow the latest gold and silver prices here too. Stay in the know on all things business with us.

Latest news on July 11, 2024: Airtel says its new Xstream Fiber plans bundle over 350 live TV channels (Official Photo) (Reuters) Disclaimer: This is an AI-generated live blog and has not been edited by Hindustan Times staff.

Follow all the updates here:

  • Thu, 11 Jul 2024 08:44 PM

    Business News LIVE Updates: Decoding Airtel’s new Xstream Fiber packages, finding value with Live TV and OTT

    • Airtel confirms to HT that the live TV proposition is being delivered using its DTH network, while the bundled streaming subscriptions are an extension of its Xstream Play platform.

    Read the full story here

  • Thu, 11 Jul 2024 03:58 PM

    Business News LIVE Updates: TCS Q1 results meet estimates: Net profit up 9%, ₹10 dividend declared

    • TCS’s consolidated revenue rose 5.4% to Rs 626.13 billion in the June quarter. Analysts had expected revenue of Rs 622.07 billion, as per LSEG data.

    Read the full story here

  • Thu, 11 Jul 2024 03:51 PM

    Business News LIVE Updates: Indian companies falsified generic Viagra data to get approval, says US FDA: Report

    • Synapse Labs Pvt. Ltd may have been used in hundreds of drugs that are still available for sale, the report said.

    Read the full story here

  • {{^userSubscribed}} {{/userSubscribed}} {{^userSubscribed}} {{/userSubscribed}}

  • Thu, 11 Jul 2024 03:09 PM

    LIVE Business News Updates: Namita Thapar’s emotional post on Emcure IPO listing: ‘Mirza Ghalib sums up my feelings’

    • Emcure Pharmaceuticals was listed at ₹1,325.05, up 31.45% on the BSE and NSE on July 10.

    Read the full story here

  • Thu, 11 Jul 2024 02:39 PM

    LIVE business news updates: Amazon could face investigation over treatment of UK food suppliers, watchdog says

    • An Amazon spokesperson said the company has made several improvements for food suppliers since last year’s results.

    Read the full story here

  • Thu, 11 Jul 2024 01:39 PM

    LIVE Business News Updates: This Bengaluru company aims to launch a ‘space habitat’ by 2027, in talks with SpaceX

    • AkashaLabdhi calls itself a “home among the stars” as it says the company’s area of ​​expertise is signal processing and continuous automation.

    Read the full story here

  • {{^userSubscribed}} {{/userSubscribed}} {{^userSubscribed}} {{/userSubscribed}}

  • Thu, 11 Jul 2024 01:10 PM

    Business News LIVE Updates: Amazon India employees on working conditions: Made to stand for hours, bathroom breaks not allowed

    • A survey conducted by UNI Global Union with the Amazon India Workers Association had 1,838 participants who alleged appalling working conditions at Amazon facilities in India.

    Read the full story here

  • Thu, 11 Jul 2024 12:44 PM

    LIVE Business News Updates: UK overhauls listing rules in bid to attract IPOs to London: What has changed?

    • The new rules allow companies to carry out more activities without putting them to a shareholder vote, the UK’s Financial Conduct Authority said.

    Read the full story here

  • Thu, 11 Jul 2024 12:18 PM

    Business News LIVE Updates: Want to send money abroad? Open foreign currency accounts at GIFT City

    • Foreign currency accounts will be like a bank account in India, but instead of rupees, you hold foreign currency like US dollars.

    Read the full story here

  • {{^userSubscribed}} {{/userSubscribed}} {{^userSubscribed}} {{/userSubscribed}}

  • Thu, 11 Jul 2024 11:30 AM

    Business News LIVE Updates: First Abu Dhabi Bank denies interest in acquiring stake in Yes Bank: Report

    • The report said the Yes Bank stake sale has attracted interest from Japan, including Mitsubishi UFJ Financial Group Inc. and Sumitomo Mitsui Financial Group Inc.

    Read the full story here

  • Thu, 11 Jul 2024 11:04 AM

    LIVE Business News Updates: TCS Share Price Surges Ahead of Q1 Results: What Brokers Say About the Stock

    • TCS Share Price: The stock opened at ₹3,944.65 against its previous close of ₹3,909.90. It then rose 1.8 percent to ₹3,979.90 level.

    Read the full story here

  • Thu, 11 Jul 2024 10:22 AM

    LIVE Business News Updates: Reliance Jio IPO listing likely in 2025 at $112 billion valuation: Jefferies

    • Jio “could list at a valuation of $112 billion” and add “7-15 percent upside” to Reliance Industries’ share price, Jefferies said.

    Read the full story here

  • {{^userSubscribed}} {{/userSubscribed}} {{^userSubscribed}} {{/userSubscribed}}

  • Thu, 11 Jul 2024 09:42 AM

    LIVE Business News Updates: Yes Bank shares rise after Moody’s revises outlook to ‘positive’ from ‘stable’

    • Global rating agency Moody’s has raised its outlook on Yes Bank to positive from “stable” despite expectations of a gradual improvement in its depositor base.

    Read the full story here

  • Thu, 11 Jul 2024 09:16 AM

    Business News LIVE Updates: Sahaj Solar IPO opens today: All you need to know before subscribing to the issue

    • Sahaj Solar IPO: The block issue aims to raise ₹52.56 crore through issuance of 2.92 million new shares and will close on July 15.

    Read the full story here

  • Thu, 11 Jul 2024 08:40 AM

    LIVE Business News Updates: Why Analysts Believe India’s Earnings Season May Disappoint Stock Market Investors

    • Investors in Indian stocks hoping for a robust earnings season to justify expensive valuations are likely to be disappointed.

    Read the full story here

  • {{^userSubscribed}} {{/userSubscribed}} {{^userSubscribed}} {{/userSubscribed}}

  • Thu, 11 Jul 2024 08:35 AM

    LIVE Business News Updates: Elon Musk Says Second Neuralink Brain Implant Will ‘Give People Superpowers’ Within a Week

    • Elon Musk said Neuralink will make some changes to try to alleviate the problem of its electrode wires retracting from brain tissue.

    Read the full story here

  • Thu, 11 Jul 2024 07:59 AM

    LIVE Business News Updates: Apple warns Indian iPhone users of possible Pegasus-like ‘spyware attack’

    • In April this year, the Indian Computer Emergency Response Team (Cert-In) flagged several vulnerabilities in Apple’s operating system for iPhone and iPad.

    Read the full story here

  • Thu, 11 Jul 2024 07:45 AM

    Business News LIVE Updates: US stock markets at record highs led by world’s biggest tech companies

    • The Philadelphia Semiconductor Index rose 2.4% to a record high after Taiwan Semiconductor Manufacturing Co. reported strong quarterly revenue.

    Read the full story here

  • {{^userSubscribed}} {{/userSubscribed}} {{^userSubscribed}} {{/userSubscribed}}

News / Business / Latest Business News Live Updates Today, July 11, 2024

Source

Continue Reading

News

Jio Financial share price: Should you buy this Reliance group stock on Monday ahead of Q1 FY2024 results?

FinCrypto Staff

Published

on

Jio Financial share price: Should you buy this Reliance group stock on Monday ahead of Q1 FY2024 results?

Q1 2024 Results: Jio Financial Share Price will be in focus on Monday as the Reliance Group company has a fixed board meeting on July 15, 2024 to consider and approve the company’s unaudited standalone and consolidated financial results. Trust Group company informed about the Q1 2024 Results date on Wednesday last week via an exchange filing. According to stock market experts, Jio Financial Services Limited is poised to deliver impressive Q1 results for FY25 on solid operating income. They have forecast a healthy QoQ PAT for the company in Q1 FY25.

Jio Financial Services News

Speaking on the Jio Financial Services Q1 2024 results, Manish Chowdhury, Head of Research, StoxBox, said, “We believe Jio Financial Services is poised to deliver impressive results in Q1FY25 aided by its operating income, which is likely to show robust growth driven by strong investment income, which in turn should lead to healthy PAT growth on a sequential basis. Jio Financial Services continues to make strategic moves such as launching digital products and expanding its ecosystem, with a clear focus on future growth. The company has announced plans to introduce products for lending against stocks and mutual funds, leveraging Jio’s large user base, which could be a significant growth driver in the coming quarters.”

“Furthermore, with the NBFC receiving RBI approval to become a primary investment company, Jio Financial Services is well-positioned to unlock value from its investments. Overall, we expect the company to report robust numbers in the upcoming quarter,” the StoxBox expert added.

Jio Financial Stock Target Price

Speaking about the technical outlook of Jio Financial share price, Ganesh Dongre, Senior Manager, Technical Research at Anand Rathi, said, “Jio Financial Services share price is poised to make a fresh high at the ₹260 apiece level. If the stock breaks above this mark, the Reliance Group stock could make a fresh high by touching the ₹290-₹295 zone. Hence, those with Jio Finance stock in their portfolio are advised to stick to the script by keeping a stop loss at ₹205. If the stock breaks above ₹260 decisively, then one can upgrade the stop loss at ₹240 for the near-term target of ₹295.”

On the advice to new buyers regarding Jio Financial stock, Ganesh Dongre said, “New buyers are advised to wait for the breakout. Once the stock breaks above ₹260, one can buy this Reliance Group stock at the short term target of ₹295, keeping a stop loss of ₹240 apiece.”

Disclaimer: The views and recommendations made above are those of individual analysts or brokerage firms, and not of Mint. Investors are advised to consult with certified experts before making any investment decisions.

3.6 Crore Indians visited in a single day choosing us as India’s undisputed platform for General Election Results. Explore Latest Updates here!

Topics that may interest you

Source

Continue Reading

Trending

Copyright © 2024 FINCRYPTO.TECH. All rights reserved. This website provides educational content and highlights that investing involves risks. It is essential to conduct thorough research before investing and to be prepared to assume potential losses. Be sure to fully understand the risks involved before making investment decisions. Important: We do not provide financial or investment advice. All content is presented for educational purposes only.